Compare UTZ & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTZ | EVO |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 912.7M | 1.3B |
| IPO Year | 2018 | N/A |
| Metric | UTZ | EVO |
|---|---|---|
| Price | $7.53 | $2.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $13.00 | $7.00 |
| AVG Volume (30 Days) | ★ 1.9M | 123.2K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,438,800,000.00 | N/A |
| Revenue This Year | $4.95 | N/A |
| Revenue Next Year | $1.59 | $7.13 |
| P/E Ratio | $730.00 | ★ N/A |
| Revenue Growth | ★ 2.09 | N/A |
| 52 Week Low | $7.26 | $2.40 |
| 52 Week High | $14.67 | $4.80 |
| Indicator | UTZ | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 26.63 | 22.23 |
| Support Level | N/A | N/A |
| Resistance Level | $10.74 | $3.78 |
| Average True Range (ATR) | 0.26 | 0.10 |
| MACD | -0.15 | -0.11 |
| Stochastic Oscillator | 11.17 | 0.18 |
Utz Brands Inc is a manufacturer of branded salty snacks. It produces a broad offering of salty snacks, including potato chips, tortilla chips, pretzels, cheese snacks, pork skins, pub/party mixes, and other snacks. Its iconic portfolio of authentic, craft, and better-for-you (BFY) brands, which includes Utz, Zapp's, On The Border, Golden Flake, and Boulder Canyon, among others, enjoys household penetration in the United States, where its products can be found in approximately half of U.S. household. The company operates in eight manufacturing facilities with a broad range of capabilities, and its products are distributed nationally to grocery, mass, club, convenience, drug, e-commerce and other retailers through direct shipments, distributors, and approximately 2,500 DSD routes.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.